We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia (STAR)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00347776
First Posted: July 4, 2006
Last Update Posted: August 7, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Eye Institute (NEI)
Project ORBIS
Information provided by (Responsible Party):
Johns Hopkins University
July 3, 2006
July 4, 2006
April 13, 2017
August 7, 2017
August 7, 2017
August 2001
December 2003   (Final data collection date for primary outcome measure)
  • Recurrent Trichiasis in Tetracycline and Azithromycin Groups [ Time Frame: Primary outcome assessed at 2 weeks,1.5 months, 6 months and 12 months post-surgery ]
    Recurrence of trichiasis : Clinical assessment was done by looking for one or more eye lashes touching globe or evidence of epilation.
  • Recurrent Trichiasis Between Two Azithromycin Arms [ Time Frame: Primary outcome assessed at 2 weeks,1.5 months, 6 months and 12 months post-surgery ]

    Recurrence of trichiasis :Clinical assessment for recurrence was done by looking for one or more eye lashes touching globe or evidence of epilation.

    If there was evidence of epilation or if one or more eye lashes were touching the globe, it was considered as recurrence of trichiasis.

recurrent trichiasis
Complete list of historical versions of study NCT00347776 on ClinicalTrials.gov Archive Site
  • Surgical Failure [ Time Frame: 6 weeks ]
    The surgery was considered a failure if one or more eye lashes were touching the globe of the eye of the subject.
  • Adverse Events [ Time Frame: 6 weeks ]
    At 6 weeks participants/family members were asked about any hospitalization,death,ocular complaints, gastrointestinal illness or other specific illness or any clinic visit within six weeks of receiving surgery.
  • Surgical Failure
  • Adverse Events
Not Provided
Not Provided
 
Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia
Trial of Antibiotics to Reduce Recurrent Trichiasis (STAR)
Trachoma, an ocular infection caused by C. trachomatis, is the second leading cause of blindness worldwide.Years of repeated infection with C. trachomatis cause the eyelid to scar and contract and ultimately to rotate inward such that eyelashes rub against the eyeball and abrade the cornea (trichiasis). The World Health Organization (WHO) has endorsed a multi-faceted strategy to combat trachoma, which includes surgery to correct trichiasis. Despite this encouraging news, under the best of circumstances the recurrence rate of trichiasis following surgery is disappointingly high. The objective of our project is to conduct a randomized, controlled clinical trial of post-surgical antibiotic treatment, comparing oral azithromycin to topical tetracycline, for trichiasis surgical patients in Ethiopia with the goal of determining the impact of treatment on rates of trichiasis recurrence at one and two years.

A randomized clinical trial of the effectiveness of a single dose of azithromycin compared to 6 weeks of topical tetracycline, and the added benefit of family-based azithromycin treatment, in preventing recurrence of trichiasis following surgery is proposed. This will provide the evidence base to inform and change the global public health policy and the donation program policy, regarding post-surgical treatment for trichiasis patients and possibly their families.

The investigators will determine the impact of three treatment strategies following trichiasis surgery on the rate of trichiasis recurrence in the operated eye at six months and one year. A randomized clinical trial of 1425 trichiasis surgical patients will be conducted in Sodo,Ethiopia. The first group (Control Group) will receive topical tetracycline following surgery; the second group (Intervention Patient Group) will receive oral azithromycin; the third group (Intervention Family Group) will receive oral azithromycin, and all family members resident in the patient's household will also receive oral azithromycin. Data will be collected at baseline (pre-surgery) on ocular status and infection status. Data will be collected at the time of surgery on surgery-related variables and surgical and post-operative complications. Additional data will be collected on any surgical complications and early recurrence at the two-week visit when sutures will be removed. A follow up visit at two months will include data collection on recurrence and presence of ocular infection. Evaluations for trichiasis recurrence will occur again at six months and at one year post-surgery. The latter visit will also include data collection on presence of ocular infection in the surgical case, and ocular infection in household members. Evaluation of the risk of recurrence at six months and one, two, and three years within each group will be completed to determine the benefit of using azithromycin compared to topical tetracycline, and the added benefit of family-based treatment.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Trichiasis
  • Drug: azithromycin
    oral antibiotic
    Other Name: Zithromax
  • Drug: topical tetracycline
  • Active Comparator: Control
    topical tetracycline
    Intervention: Drug: topical tetracycline
  • Active Comparator: Intervention 1
    oral azithromycin, single 1g dose to subject
    Intervention: Drug: azithromycin
  • Active Comparator: Intervention 2
    single oral azithromycin dose to subject and immediate family members
    Intervention: Drug: azithromycin

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1452
December 2006
December 2003   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Presence of trichiasis:
  • no previous report of trichiasis surgery in at least one eye with trichiasis:
  • Agreement by at least one other family member accompanying the patient that, if the patient is randomized to the family-treatment arm, s/he also would be willing to receive antibiotic treatment
  • Age 18 or older

Exclusion Criteria:

  • other household members concurrently participating in the trial
  • Self-reported pregnancy
  • Documented allergy to tetracycline
  • Plans to move out of the region within 1 year.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00347776
U01EY013878( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Johns Hopkins University
Johns Hopkins University
  • National Eye Institute (NEI)
  • Project ORBIS
Principal Investigator: Sheila K West Johns Hopkins University
Johns Hopkins University
June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP